

## **REMARKS**

### **Amendments / Status of Claims**

In this paper, claims 1, 3, 7, 21-27, 30-31, 34 and 36-37 have been cancelled without prejudice or disclaimer. Claims 2, 4, 11, 19, 28, 29 and 35 have been amended. Support for the amendments can be found throughout the specification. No new matter has been added.

The amendment and/or cancellation of claims is without prejudice or disclaimer of the subject matter thereof and was done solely to expedite prosecution of the present application. Applicants reserve the right to pursue the original subject matter of this application in a later-filed application claiming benefit of the instant application, including without prejudice to any determination of equivalents of the claimed subject matter.

After entry of the amendment, claims 2, 4-6, 8-20, 28-29, 32-33 and 35 are pending in the instant application.

### **Response to Restriction Requirement**

In response to the Restriction Requirement, Applicants elect with traverse the invention of Group I, claims 2, 4-6, 8-20, 28-29, 32-33 and 35 drawn to pyrazolo[1,5-a] pyrimidines.

Moreover, solely to comply with the requirement that Applicants select a single disclosed species (which Applicants understand to refer to a specific chemical compound), Applicants elect with traverse the compound disclosed in the application as Compound of Example 1047 in the subject application: (5R)-N-(1-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide.

It is believed that, of the selected claims, at least claims 2, 4-6, 8-15, 17, 19-20, 28-29, 32-33 and 35 read upon the elected species.

The selection of Group I and the above election of species are made to comply with the Restriction Requirement, without prejudice, and the right to file divisional applications on non-elected subject matter is reserved.

Conclusion

Early consideration and allowance of the application are earnestly solicited.

Although it is not believed that any extensions of time, or additional fees, are needed to consider this submission, Applicants request any extension of time necessary for consideration of this response, and the Examiner is hereby authorized to charge our deposit account no. 04-1105 under order no. 66585 (70820) should any fee be deemed necessary.

Dated: November 19, 2007

Respectfully submitted,

By /Mark D. Russett/  
Mark D. Russett, Registration No.: 41,281  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, MA 02205  
(617) 239-0100  
Attorneys/Agents for Applicant(s)